Healthcare Innovation April 30, 2021
“The data available through MyCode provides us with a unique opportunity to investigate the genetic risk of cancer in a large regional population,” says Geisinger’s David J. Carey, Ph.D.
Researchers at the Geisinger health system in Pennsylvania are studying the role of genetic variation in cancer with a $3.6 million grant from the National Cancer Institute.
Geisinger researchers and the NCI’s Division of Cancer Epidemiology and Genetics (DCEG) will analyze genetic data from Geisinger’s MyCode Community Health Initiative, a precision medicine project with more than 276,000 consented participants.
The investigative team will use a “genome-first” approach, analyzing data from MyCode participants to identify specific gene variants and then linking that information to the participants’ electronic health records. This approach...